DATABASE · 2,000+ PEER-REVIEWED CITATIONS INDEXEDCOMPOUND LIBRARY · 100+ EVIDENCE-GRADED RECORDSGRADE A EVIDENCE · 45 COMPOUNDS WITH MULTIPLE HUMAN RCTSHUMAN EVIDENCE · 97 COMPOUNDS WITH HUMAN STUDY DATAVENDOR DIRECTORY · 11 RESEARCH VENDORS TRACKEDCLINIC DIRECTORY · 10 TELEHEALTH PROVIDERS VETTEDCOA RECORDS · 7 BATCH CERTIFICATES ON FILELIVE DATABASE · UPDATED 2D AGODATABASE · 2,000+ PEER-REVIEWED CITATIONS INDEXEDCOMPOUND LIBRARY · 100+ EVIDENCE-GRADED RECORDSGRADE A EVIDENCE · 45 COMPOUNDS WITH MULTIPLE HUMAN RCTSHUMAN EVIDENCE · 97 COMPOUNDS WITH HUMAN STUDY DATAVENDOR DIRECTORY · 11 RESEARCH VENDORS TRACKEDCLINIC DIRECTORY · 10 TELEHEALTH PROVIDERS VETTEDCOA RECORDS · 7 BATCH CERTIFICATES ON FILELIVE DATABASE · UPDATED 2D AGO
Home/Compounds/AOD-9604
Other

AOD-9604

Also known as: Anti-Obesity Drug 9604 · Tyr-hGH Fragment 177-191

Modified GH fragment studied for fat loss without GH side effects, TGA approved in Australia.

B
Grade B
Human observational studies
Human studies8
PubMed citations8
Typical dose250 mcg – 500 mcg
Routesubcutaneous, oral
Regulatory (US)Compounding legal
Last verified4 days ago
TL;DR · 30-second summary
  • Stimulates lipolysis without GH side effects
  • No effect on IGF-1 or blood glucose
  • TGA approved for osteoarthritis (Australia)
  • Phase 2 obesity trials showed modest results

Mechanism of action

Modified fragment of human growth hormone (amino acids 177-191). Mimics lipolytic effects of GH without affecting blood sugar or growth. Does not bind GH receptors.

Evidence summary

8
Human studies
8
PubMed citations
0
Clinical trials
B
Evidence grade

Phase 2 trials showed modest fat loss. TGA approved in Australia for osteoarthritis. Did not meet endpoints for obesity indication.

Dosing protocols

Educational information only. Consult a licensed provider before using any peptide.
Dose range
250 mcg – 500 mcg

250-500mcg daily, typically morning fasted. Some protocols use 300mcg twice daily.

Administration routes
subcutaneousoral

Side effects & safety

Reported side effects
Generally well toleratedInjection site reactionsHeadache (rare)
Contraindications
  • Active malignancy
  • Pregnancy

Interactions

No documented drug interactions on file.

Regulatory status

United States
Not FDA approved

Not FDA approved. Research chemical. TGA approved in Australia.

Compounding
Permitted

Available through compounding pharmacies with valid prescription.

Regulatory data last verified 4/17/2026

Clinical trials

No indexed ClinicalTrials.gov studies for AOD-9604. This usually means the compound isn't being studied under an IND — check the citations section for peer-reviewed research instead.